Methods. We employed a mix method approach, first distributing a survey to all full-time prescribers. We then followed up with qualitative interviews (12 of 22 prescribers) which was conducted by a single, trained interviewer using a standardized guide. Interviews were recorded and transcribed verbatim. Each transcription was independently reviewed and coded by two blinded investigators using standardized themes and adjudicated by a third investigator for stability, robustness, and interrater reliability. Individually, researchers identified and coded key themes and statements. These themes were then discussed as a group and combined where they shared meaning. This project was reviewed and deemed to be non-human subjects research by the Stanford University School of Medicine Panel on Human Subjects in Medical Research.

**Results.** A total of 20 of the 22 prescribers (13 MDs and 9 APPs) completed the survey (91% response rate). Notably, only 25% of prescribers agreed that COVID-19 had changed their antibiotic prescribing practices for patients with respiratory infections despite objective data that all prescribed less. In the qualitative interviews, we identified four major themes impacting the appropriateness of antibiotic prescribing practices as shown in Table 1.

able 1. Qualitative themes from prescriber interv
Patient expectations and knowledge
Patients more concerned about COVID-19 than
bacterial infection There's more focus on COVID and viral illnesses than on bacterial illnesses. So in a regular year that same viral illness can be misinterpreted as a bacterial infection, but this year I think the focus was on COVID so most patients were fine with having a negative COVID study and taking care of the COVID So most patients were pine wan invarig a negative Covid study and soning size of the symptoms on their own versus going for an antibiotic for their sinus symptoms.

The concerns that are on patient's minds are not a bacterial infection, the concern is a COVID infection, so they're not necessarily requesting antibiotics they're requesting a COVID test. I think th ents sought COVID-19 testing rather than has changed the demands on the provider and so they're not pressured to prescribe antibiotics.

I think in a way COVID-19 has helped us be able to educate patients about viral infections and h itients more aware that antibiotics do not treat I think in a way COVID-19 has helped us be able to educate patients about viral infections and neap them anderstand by learning about viruses a little bit more, that on antiblotic is not agong to text. It Because of COVID and the understanding now, patients are a little bit more receptive to the fact that they understand now what is virul, which is bacterial. (Not everybody, but think that with some patients, I think it's easier to explain to them than before. It's easier to have that conversation I feel iral infections Educating patients on viral vs. bacterial infection patents, I think it's easier to explain to them than before. It's easier to have that conversation [refer now, than before house people or a little it more oware obtain pare respirately reference. It's also possible that all of us as providers kind of got a little binary. It's either COVID or it's not COVID. All the cover of the cover of the covider liagnosis and treatment rescriber differential diagnosis centered around OVID-19 ack of efficacy of antibiotics against COVID-19 Telemedicine Limited physical exam efinitely be necessary for me to even consider prescribing an antibiotic. It's a telemedicine visit it's a little bit easier to say no to somebody who isn't sitting right next ti refusing to prescribe antibiotics easier in a elemedicine visit vs. in-person Just in case" antibiotic prescribing due to you.

Telehealth has created a whole new sort of opportunity for prescribing, especially "just in case medicines." I don't think this is what it is, but I think the consequences of me missing this diagnost because I can't actually see you or feel you or hear you is worse than me just giving you the Changing non-COVID-19 infection epidemiology feel like we're seeing a lot less upper respiratory infections in general, far fewer cold and flu visits han we normally would. And it's all the education available this year, I think that's playing a big role In bis. It could also be that people are not getting as sick this year. Staying inside, people are wearin nasks, so there's less people with upper respiratory infections this year. ns, influenza, bronchitis

Conclusion. Urgent care prescribers attributed a decrease in antibiotic prescribing during COVID-19 to changes in patient expectations and knowledge base, a switch to telemedicine-based encounters, and changing epidemiology. These shifts could be utilized by outpatient antimicrobial stewardship efforts to sustain low prescribing rates for conditions in which antibiotics are generally not indicated.

Disclosures. Marisa Holubar, MD, MS, Nothing to disclose

**161.** Flucytosine Utilization and Dosing Practices at an Academic Medical Center Molly M. Miller, PharmD<sup>1</sup>; Emily Kreikemeier, MPH, PharmD, BCPS<sup>1</sup>; Erica J. Stohs, MD, MPH<sup>2</sup>; Trevor C. Van Schooneveld, MD, FACP<sup>2</sup>; Trevor C. Van Schooneveld, MD, FACP<sup>2</sup>; Bryan Alexander, PharmD<sup>1</sup>; Scott J. Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP<sup>1</sup>; Scott J. Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP<sup>1</sup>; Nebraska Medicine, Bellevue, Nebraska; <sup>2</sup>University of Nebraska Medical Center, Omaha, NE

Session: P-09. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

**Background.** The typical dose of flucytosine is 25 mg/kg/dose every 6 hours for severe infections due to *Candida* and *Cryptococcus*. Many hospital protocols use ideal body weight (IBW) for initial dosing to achieve a goal peak serum concentration of 30-80 mcg/mL, but this is supported by very limited data. Our objective was to evaluate flucytosine dosing strategies, describe safety concerns, and explore financial benefits associated with using IBW.

*Methods.* All inpatient flucytosine orders for adults from 1/1/2015 through 10/31/2020 were retrospectively evaluated. Doses, weight used, flucytosine levels, adverse events, and potential cost savings associated with IBW dosing were characterized.

**Results.** During this period, 35 patients received flucytosine. The most common indications were cryptococcal meningitis (73%), pulmonary cryptococcosis (14%), and candidiasis (11%). Most patients were receiving concurrent liposomal amphotericin B (92%). Based on body mass index, most patients were overweight or obese (60%). Actual body weight was used for initial dosing in most cases (81%). Flucytosine peak monitoring was performed in 51% of cases. Initial peak levels were supratherapeutic in 10/19 cases (53%). Of those 10 patients, 70% were overweight/obese, and 60% would have received a lower initial dose if IBW had been used with dose rounding to the nearest 500mg capsule. Adverse events for all patients included new onset cytopenias, hepatic and renal dysfunction, occurring in 20%, 11%, and 60% respectively. Those with supratherapeutic levels had higher rates of new onset hepatic and renal dysfunction, 30% and 90% respectively. In 32% of cases, using IBW would have resulted in a lower daily dose, with an average dose reduction of 1888 mg, resulting in a mean cost savings per patient of \$640/day using average wholesale price.

Conclusion. Most flucytosine orders were not dosed using IBW, which may have led to supratherapeutic levels. Using IBW for dosing in overweight patients may lead to reduced toxicity and potential cost savings. The default dosing weight for flucytosine in our electronic medical record will be set to IBW to encourage change.

Disclosures. Trevor C. Van Schooneveld, MD, FACP, BioFire (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Insmed (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck

(Individual(s) Involved: Self): Scientific Research Study Investigator; Rebiotix (Individual(s) Involved: Self): Scientific Research Study Investigator Bryan Alexander, PharmD, Astellas Pharma (Advisor or Review Panel member) Scott J. Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP, Merck & Co., Inc (Grant/Research Support) Scott J. Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP, Merck & Co., Inc (Individual(s) Involved: Self): Research Grant or Support

## 162. Duration of Antibiotics Through Care Transitions: A Quality Improvement Initiative

Caitlin Soto, PharmD¹; Kate Dzintars, PharmD²; Kate Dzintars, PharmD²; Sara C. Keller, MD, MPH, MSPH³; ¹The Johns Hopkins Hosiptal, Baltimore, Maryland; ²The Johns Hopkins Hospital, Baltimore, Maryland; ³Johns Hopkins University School of Medicine, Baltimore, MD

Session: P-09. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

**Background.** Antibiotic resistance is increasing worldwide, largely driven by excessive antibiotic use. Antibiotic stewardship (AS) interventions have traditionally focused on acute care, long-term care, and ambulatory settings. However, as patients transition from one care setting to another, AS interventions should address antibiotic orders (agent, dose, duration) between the hospital and the home. The purpose of this study is to determine the appropriateness of a total course of antibiotics, including inpatient and outpatient prescriptions, to aid in prioritizing AS interventions.

**Methods.** A single-center, retrospective study was performed to evaluate antibiotic duration for adult patients discharged from a large quaternary-care academic hospital. All antibiotic prescribing data, including pre-admission, during admission, and after hospital discharge, as well as information on indication, was collected from the electronic medical record. Descriptive statistics were used to summarize the data collected.

Results. 196 patients were included in the study. There were 100 instances of disagreement on antibiotic indication between the discharge summary and reviewer. However, 70% of patients were discharged on an appropriate antibiotic. The majority of patients (75%) were prescribed excess antibiotic days beyond guideline recommended total duration, and 68% of patients did not have appropriate duration of antibiotics post-discharge. Of those with excess duration, 31% were prescribed penicillins, 23% were prescribed cephalosporins, and 20% were prescribed trimethoprim/sulfamethoxazole. Excess antibiotic duration was associated most commonly with an unknown diagnosis (23%), a skin and soft tissue infection diagnosis (16%), and antibiotic prophylaxis (12%).

Conclusion. The results of this study showed that patients were often prescribed excess antibiotics at discharge, and the total duration of antibiotics from pre-admission to post-discharge were prolonged beyond guideline-recommended duration. Understanding the total duration of antibiotic prescription, including post-discharge and pre-admission durations, is key in assessing risk from antibiotics and targeting AS interventions.

Disclosures. Kate Dzintars, PharmD, Nothing to disclose

## 163. MIC Shifts in Response to Increased Antibiotic Utilization During COVID-19 Pandemic

Jonathan Byrd, MD¹; Neena Thomas-Gosain, MD²; Jane V. Eason, MD³; Jessica Bennett, PharmD.⁴; Jarred Bowden, Pharm.D., BCIDP, AAHIVP⁵; ¹UTHSC, Memphis, Tennessee; ²University of Tennessee Health Science Center, Memphis, Tennessee; ³Memphis VA Medical Center; UTHSC, Memphis, Tennessee; ⁴VAMC Memphis, Germantown, Tennessee; ⁵Memphis VA Medical Center, Memphis, Tennessee

Session: P-09. Antimicrobial Stewardship: Trends in Antimicrobial Prescribing

**Background.** Multiple studies have shown that antibiotic utilization increased during the COVID-19 pandemic. However, the impact of this increased utilization has not been well established. The aim of this study is to describe the trends in minimum inhibitory concentrations for various antibiotics against common gram-negative pathogens observed since the start of the COVID-19 pandemic as compared to previous years.

Methods. This retrospective study was conducted at the Memphis VA. All respiratory, urine, and blood culture MicroScan results run from October 2017-March 2021 were analyzed. Only inpatient and emergency department data was included. The MIC50 and MIC90 of seven antibiotics for four of the most common pathogens were trended by quarterly intervals.

**Results.** MIC50 and MIC90 were compared using standardized breakpoints. As compared to previous years, *Pseudomonas aeruginosa* was noted to have the most sustained increase in MIC90 across various antibiotics. In the last 3 quarters of the study time frame, piperacillin-tazobactam mean MIC90 increased from 32 to 64, cefepime from 8 to > 16, and meropenem from 4 to > 8. *Escherichia coli* had a sustained increase in ceftriaxone MIC90 from < 1 to > 8 in the final quarter of 2020 and beginning of 2021. *Klebsiella pneumonia* was also found to have a sustained increase in cefepime mean MIC90 from < 1 to > 16 during the year of 2020, with return to previous MIC90 the following quarters.

Conclusion. Previous studies have clearly demonstrated a widespread increase in antibiotic utilization during the COVID era. Our study demonstrates how even short-term increases in antibiotic use can lead to shifts in MIC, if not outright resistance. This was demonstrated across multiple common gram-negative pathogens and to various broad-spectrum antibiotics which were commonly used more frequently during COVID-19. Further analysis will be needed to determine whether these trends